CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 132 enrolled
Drug / intervention
solifenacin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00431041
NCT00431041Phase 4Completed
CompareCT.gov

VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients

Astellas Pharma Inc·interventional·Posted Feb 2, 2007·Updated Jun 8, 2010

In Brief

A Phase 4 clinical trial evaluating solifenacin and oxybutynin immediate release for Overactive Bladder. Completed, enrolled 132 participants across 12 sites.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesCanada
CollaboratorsAstellas Pharma Canada, Inc.

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2007
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.4 years ago

Interventions

solifenacindrug

Oral

oxybutynin immediate releasedrug

Oral